Recce Pharmaceuticals

Recce Pharmaceuticals ROE

The Return on Equity (ROE) of Recce Pharmaceuticals (RCE.AX) as of Oct 28, 2026 is 89.47 %. In the previous year, Return on Equity (ROE) was 702.10 % — a change of -87.26% (lower).

ROE

89.47 %

YoY

-87.26%

Last updated:

In 2026, Recce Pharmaceuticals's return on equity (ROE) was 89.47 %, a -87.26% increase from the 702.10 % ROE in the previous year.

The Recce Pharmaceuticals ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
687.67 AUD
Jan 1, 2020
-186.66 AUD
Jan 1, 2021
-65.91 AUD
Jan 1, 2022
-109.19 AUD
Jan 1, 2023
505.15 AUD
Jan 1, 2024
185.45 AUD
Jan 1, 2025
702.10 AUD
Jan 1, 2026
89.47 AUD
The Recce Pharmaceuticals ROE history
YEARROEYoY
89.47 %-87.26%
702.10 %+278.59%
185.45 %-63.29%
505.15 %-562.62%
-109.19 %+65.68%
-65.91 %-64.69%
-186.66 %-127.14%
687.67 %-385.42%
-240.93 %-53.00%
-512.67 %+272.17%
-137.75 %+1,342.51%
-9.55 %-101.97%
484.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

ROE Details

Decoding Recce Pharmaceuticals's Return on Equity (ROE)

Recce Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Recce Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Recce Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Recce Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Recce Pharmaceuticals stock

Return on Equity (ROE) of Recce Pharmaceuticals is 89.47 % in 2026.

Return on Equity (ROE) of Recce Pharmaceuticals changed from 702.10 % to 89.47 %, representing a -87.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Recce Pharmaceuticals

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Recce Pharmaceuticals